Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has entered into a long-term agreement with Thermo Fisher Scientific Inc (NYSE: TMO) to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology.

• Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, Spikevax.

• As a part of the 15-year expanded deal, Thermo Fisher would provide dedicated manufacturing capacity in the U.S. for fill/finish services and labeling and packaging services for Spikevax and other mRNA drugs in Moderna's pipeline.

• Moderna last week said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its COVID-19 shot, including one for viral infection shingles.

• On Tuesday, Moderna also announced a partnership with Adium Pharma S.A. to distribute its COVID-19 vaccine in Latin America.

• Price Action: TMO shares are up 1.08% at $535.60, MRNA stock is down 5.77% at $136.60 during the market session on the last check Wednesday.

See more from Benzinga

• Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

• Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.